Document Detail


Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes.
MedLine Citation:
PMID:  17478457     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: Late-acquired incomplete stent apposition (ISA) has been documented after drug-eluting stent (DES) implantation; however, its clinical role remains controversial. We sought to investigate the incidence and long-term clinical consequences of late ISA after implantation of sirolimus- (SES) or paclitaxel-eluting stent (PES) in a non-selected population. METHODS AND RESULTS: From our database, we analysed 195 consecutive patients who underwent DES placement (175 with SES and 20 with PES) into native artery lesions and had serial intravascular ultrasound studies (IVUS) performed at index procedure and after 6-8 months. They were clinically followed for 29 +/- 15 months (median of 24.3 months, interquartile range 18.1-31.6 months). Late ISA was defined as separation of at least one stent strut from the vessel wall in a segment without a side-branch and where the immediate post-implantation IVUS revealed complete apposition of stent struts. We identified 10 patients (5.1%) with late ISA, three patients after PES, and seven patients after SES implantation. ISA was localized almost exclusively at body of the stents (nine out of 10 cases). Mean ISA volume and length were 44.5 +/- 41.9 mm(3) and 7.4 +/- 11 mm, respectively. There was a marked increase in vessel volume from 416.0 +/- 163.9 mm(3) at baseline to 514.4 +/- 247.9 mm(3) at follow-up (P = 0.001) with no significant change in plaque volume (232.4 +/- 52.7 at baseline and 226.4 +/- 22.3 mm(3) at follow-up, P = 0.3) in patients who presented with late-acquired ISA. During the follow-up period, one patient with SES and one patient with PES who presented late-acquired ISA had late stent thrombosis and acute myocardial infarction. CONCLUSION: Late-acquired ISA was observed in 5.1% of patients after DES implantation and is related to regional vessel positive remodelling. The relationship between late-acquired ISA and long-term adverse outcomes (e.g. stent thrombosis) requires further analysis.
Authors:
Dimytri A Siqueira; Alexandre A Abizaid; Jose de Ribamar Costa; Fausto Feres; Luiz A Mattos; Rodolfo Staico; Andrea A Abizaid; Luiz F Tanajura; Aurea Chaves; Marinella Centemero; Amanda G M R Sousa; J Eduardo M R Sousa
Related Documents :
22041717 - Second-generation arthroscopic autologous chondrocyte implantation for the treatment of...
23434307 - Is benign paroxysmal vertigo of childhood a migraine precursor?
18288747 - Comparison of a polymer-free rapamycin-eluting stent (yukon) with a polymer-based pacli...
19901407 - Three-year survival after percutaneous coronary intervention according to appropriatene...
11501607 - Long-term follow-up after deferring angioplasty in asymptomatic patients with moderate ...
7074337 - The use of jejunal interposition for intractable symptoms complicating peptic ulcer sur...
Publication Detail:
Type:  Journal Article     Date:  2007-05-03
Journal Detail:
Title:  European heart journal     Volume:  28     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-05-31     Completed Date:  2007-12-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  1304-9     Citation Subset:  IM    
Affiliation:
Instituto Dante Pazzanese de Cardiologia, Rua Dr Dante Pazzanese 500, CEP 04012-909 São Paulo, SP, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Vessel Prosthesis
Drug-Eluting Stents*
Female
Graft Occlusion, Vascular / etiology
Humans
Immunosuppressive Agents / administration & dosage*
Male
Middle Aged
Myocardial Infarction / therapy*,  ultrasonography
Myocardial Revascularization
Paclitaxel / administration & dosage*
Prosthesis Failure
Sirolimus / administration & dosage*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus
Comments/Corrections
Comment In:
Eur Heart J. 2007 Jun;28(11):1275-6   [PMID:  17493941 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mechanical and cold hypersensitivity in nerve-injured C57BL/6J mice is not associated with fear-avoi...
Next Document:  The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponi...